EP3515563A1 - Detergent product for cosmetic use - Google Patents

Detergent product for cosmetic use

Info

Publication number
EP3515563A1
EP3515563A1 EP17791732.5A EP17791732A EP3515563A1 EP 3515563 A1 EP3515563 A1 EP 3515563A1 EP 17791732 A EP17791732 A EP 17791732A EP 3515563 A1 EP3515563 A1 EP 3515563A1
Authority
EP
European Patent Office
Prior art keywords
product
base compound
detergent
probiotic bacteria
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17791732.5A
Other languages
German (de)
French (fr)
Other versions
EP3515563B1 (en
Inventor
Alberto RODOLFI
Elisabetta CASELLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Copma SCARL
Original Assignee
Copma SCARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Copma SCARL filed Critical Copma SCARL
Priority to RS20211118A priority Critical patent/RS62316B1/en
Priority to PL17791732T priority patent/PL3515563T3/en
Priority to SI201730893T priority patent/SI3515563T1/en
Priority to HRP20211440TT priority patent/HRP20211440T1/en
Publication of EP3515563A1 publication Critical patent/EP3515563A1/en
Application granted granted Critical
Publication of EP3515563B1 publication Critical patent/EP3515563B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40—Viruses, e.g. bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/14—Preparations for removing make-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q9/00—Preparations for removing hair or for aiding hair removal
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/381—Microorganisms

Definitions

  • the present invention relates to the technical sector relating to cosmetic treatments for topical use, in the field of detergents.
  • the bacteria of the Bacillus genus represent a vast group of spore-forming Gram-positive bacteria, ubiquitous in nature and also present in the human intestine.
  • the spores formed by the Bacillus bacteria can survive for very long times, because of their resistance to desiccation, heat and many chemical substances, and are therefore ideal for probiotic applications in the field of cosmetics. It is also noteworthy that from the point of view of safety, the Bacillus species present in the products used are considered low/null risk for pathogens (non-pathogenic).
  • the presence of the probiotics further prevents re-colonisation by contaminant micro-organisms, thus stably maintaining the hygiene where the probiotics are applied.
  • An aim of the present invention is to obviate the above drawbacks by providing a detergent product for cosmetic use able to act rapidly and effectively against any potentially-dangerous microbial species, including those of the multi-resistant type (superbugs).
  • the above-indicated aims are obtained by a cosmetic product realised according to claim 1 , and a use of the cosmetic product according to claim 10.
  • the product for cosmetic use comprises the following compounds, in combination:
  • the base compound can be in the solid, liquid or gaseous state
  • the base compound can comprise at least cationic surfactants, anionic surfactants or amphoteric compounds or mixtures thereof;
  • the base compound can comprise: PEG-6-caprylic/capric glycerides; Sodium laureth sulfate; Sodium lauryl sulfate; Acrylates/steareth-20 methacrylate copolymer; phenoxyethanol; ethylhexylglycerin, potassium hydroxide;
  • the probiotic bacteria spores are mixed with the base compound at a concentration comprised between 10 2 -10 9 spores/ml; ⁇ the bacteriophage elements are mixed with the base compound at a concentration comprised between 10 3 -10 9 PFU/ml;
  • the probiotic bacteria are of the Bacillus genus (preferably though not exclusively of the species Bacillus subtilis, Bacillus megaterium and Bacillus pumilus);
  • the bacteriophage elements comprise bacteriophages of the family Caudovirales and/or of the family Microviridae and/or of the family Leviviridae and/or of the family Inoviridae and/or of the family Tectiviridae and/or of the family Corticoviridae;
  • Figures 1-3 are graphs relating to colonisation over time, respectively to Staphylococcus aureus, Enterobacteriaceae spp. Gram negative) and Candida albicans, on surfaces treated with probiotic bacteria.
  • Figures 4-6 are graphs relating to colonisation over time, respectively to Staphylococcus aureus, Enterobacteriaceae spp. Gram negative) and Candida albicans, on surfaces treated with bacteriophages.
  • Figures 7-9 are graphs relating to colonisation over time, respectively to Staphylococcus aureus, Enterobacteriaceae spp. Gram negative) and Candida albicans, on surfaces treated with bacteriophages and with probiotic bacteria.
  • Figure 10 is a graph relating to colonisation over time, with respect to Staphylococcus aureus on surfaces treated with probiotic bacteria and with bacteriophages, with respect to surfaces treated only with probiotic bacteria and only with bacteriophages.
  • the proposed detergent product for cosmetic use innovatively comprises: - a base compound having a detergent action;
  • bacteriophage elements mixed with the base compound and having bactericide activity on predetermined undesired bacterial species present, the bacteriophage elements, in cooperation with the spores of probiotic bacteria, being able to carry out a combined and synergic action against damaging micro-organisms.
  • the field of the invention also includes the use of the detergent product for cosmetic use for cleansing of the skin, skin adnexa (hair, body hair, keratin fibres, nails, beard), of the oral cavity, mucosa (in particular of the oral cavity) and the teeth. It is particularly advantageous for the cleansing of the skin, skin adnexa, hair, nails, body hair, beard, for external intimate hygiene.
  • the base compound can comprise one or more of the following: PEG-6- caprylic/capric glycerides; Sodium laureth sulfate; Sodium lauryl sulfate; Acrylates/steareth-20 methacrylate copolymer; phenoxyethanol; ethylhexylglycerin, potassium hydroxide. To these can also be added cocamidopropyl betaine and dodecyl-betaine.
  • the spores of probiotic bacteria can be present in the detergent product of the invention, at a concentration comprised between 10 2 -10 9 spore/ml, preferably from 10 5 -10 9 spore/ml, more preferably 10 6 -10 8 spore/ml.
  • the bacteriophage elements specifically directed against bacteria potentially able to cause infection/inflammation of the skin or adnexa can be present in the detergent product of the invention, at a concentration comprised between 10 3 -10 9 spore/ml, preferably from 10 5 -10 9 spore/ml, more preferably 10 6 -10 8 spore/ml.
  • the probiotic bacteria can be of the Bacillus genus, including the species Bacillus subtilis, Bacillus megaterium and Bacillus pumilus.
  • the bacteriophage element can advantageously be selected, alternatively or in combination, according to the bacterial species to be compared, from among the following families: Caudovirales, Microviridae, Leviviridae, Inoviridae, Tectiviridae, Corticoviridae.
  • the bacteriophage elements of the Caudovirales family also comprise the Myoviridae, Siphoviridae, Podoviridae families.
  • the detergent product of the invention for cosmetic use is particularly suitable for cleansing of the skin, skin adnexa (hair, body hair, keratin fibres, nails), the oral cavity, the mucosa (in particular of the oral cavity) and teeth.
  • It can be produced in the solid state (for example for soaps, powders etc.) or in the liquid state (for example creams, lotions, gels, foams etc.) or in the gaseous state (for example for sprays etc.) or an emulsion or a suspension or a paste (for example a toothpaste).
  • the detergent product for cosmetic use can be advantageously a toothpaste, a soap, a beauty soap, a deodorant soap, a depilating soap, a shaving soap or foam, a make-up removing product for the face and/or eyes (for example a detergent milk, micellar water, tonic), a foam bath, a shower bath, an intimate detergent for external use, a liquid shampoo, a powder shampoo, a hair conditioner balsam, a deodorant, an anti-perspirant product, or a bath salt.
  • a toothpaste for example a detergent milk, micellar water, tonic
  • a foam bath for example a detergent milk, micellar water, tonic
  • a shower bath for intimate detergent for external use
  • a liquid shampoo for example a powder shampoo, a hair conditioner balsam, a deodorant, an anti-perspirant product, or a bath salt.
  • the detergent product for cosmetic use is a toothpaste, a soap, a beauty soap, a deodorant soap, a depilating soap, a shaving soap or foam, a make-up removing product for the face and/or eyes (for example a detergent milk, micellar water, tonic), a foam bath, a shower bath, an intimate detergent for external use, a liquid shampoo, or a powder shampoo.
  • bath and/or shower products can be in liquid form, such as a liquid detergent product, a foam, oils, gels, or they can be in the form of salts and are preferably a liquid detergent, and oil or a gel.
  • the detergent product for cosmetic use of the invention is a product for shaving such as, for example, a shaving cream, foam or lotion, or a depilating soap, and more preferably it is a cream, a shaving foam or a depilating soap.
  • a product for shaving such as, for example, a shaving cream, foam or lotion, or a depilating soap, and more preferably it is a cream, a shaving foam or a depilating soap.
  • the shaving creams or foams and the depilating soaps of known type comprise a base compound having a detergent activity and in fact once rinsed they cleanse the skin and the adnexa.
  • the detergent product for cosmetic use according to the invention for shaving or depilation is preferred.
  • the detergent product for cosmetic use of the invention is a product for oral hygiene, in particular a toothpaste, in particular if in paste, gel or powder form. The use thereof for cleaning the teeth and/or the mucous membranes of the oral cavity is consequently advantageous.
  • the detergent product for cosmetic use of the invention is a make-up removal detergent for the face and/or eyes. It is consequently advantageous to use the product for cleansing the face and/or the eyes of make-up.
  • the action of the bacteriophages is specific, as specific types of lithic bacteriophages kill specific types of bacteria, and therefore perform a potentially very effective and specific action in the direct battle against undesired bacteria.
  • bacteriophages in detergent products for cosmetic use is particularly indicated as they are rather stable in differing temperature conditions, pH and salinity of the environment, and can therefore be added to base compounds without suffering in terms of activity and without the base compound losing detergent activity.
  • PCHS detergents containing probiotics have been amply evaluated on inert surfaces, where they have shown themselves to be able to destroy the microbial load by about 90% more with respect to traditional detergents, with protracted use for about one month.
  • Figures 1 -3 illustrate the antimicrobial action (bacteria and fungi) of detergent product based only on probiotics.
  • Figure 4-6 illustrate the anti-bacterial action of the bacteriophages on an inert surfaces contaminate by specific target bacteria.
  • Staphylococcus aureus taken as an example of Gram positive bacteria
  • Pseudomonas aeruginosa as an example of Gram negative bacteria
  • Candida albicans as an example of fungi
  • the surfaces were contaminated with a known quantity of micro-organism (10 2 CFU/24 cm 2 ) and then treated by application of growing concentrations of specific bacteriophages (respectively 10 3 , 10 4 , 10 5 PFU), therefore in ratios of 10:1 , 100:1 and 1000:1 with the seeded target bacteria.
  • the residual contamination was evaluated after 1 , 3, 6 hours by application of Rodac plates of specific medium for the indicated bacterial and fungi species. The results are expressed as mean values ⁇ S.D. of samples in duplicate in three independent experiments.
  • the bacteriophages are able to remove more than 90% of the bacterial cells against which they are specifically directed.
  • the treatment with only bacteriophages has the limitation of being directed only against the bacteria specifically recognised by the bacteriophages, and therefore in a case of contamination by bacterial species different from those against which the bacteriophages are specifically directed, the surface treated is contaminated by the species not attacked by the bacteriophages, as the bacteriophages are by definition specific for a bacterial species, and therefore not able to attack other bacterial species, not are they able to attack species of fungi.
  • Figures 7-9 illustrate the effect of the combined and synergic antimicrobial action obtained with the contemporary presence of probiotic bacteria and bacteriophages on surfaces contaminated by the specific microbes illustrated.
  • the surfaces were contaminated with a known quantity of micro-organism (10 3 CFU/24 cm 2 ) and then treated by application of a solution containing probiotic bacteria growing concentrations of (10 3 CFU/ml) and specific bacteriophages (10 4 PFU/ml).
  • the residual contamination was evaluated after 1 , 2, 3 and 4 hours by application of Rodac plates of specific medium for the indicated bacterial and fungi species.
  • the results are expressed as mean values ⁇ S.D. of samples in duplicate in three independent experiments.
  • Figure 10 illustrates the direct comparison between the antimicrobial action of the no. 3 treatments on the contamination by Staphyococcus aureus, measured in vitro on experimental models of inert surfaces of 24 cm 2 .
  • the surfaces were contaminated with a known quantity of micro-organism (10 3 CFU/24 cm 2 ) and then treated by application of a solution containing probiotic bacteria growing concentrations of (10 3 CFU/ml), only specific bacteriophages (10 4 PFU/ml), or the combination of probiotics and bacteriophages at the indicated concentrations.
  • the residual contamination was evaluated after 1 , 2, 3 and 7 hours by application of Rodac plates of specific medium for Staphyococcus aureus.
  • the bacteriophages destroy the contaminant load extremely rapidly, but have a limited action over time and do not succeed in preventing re-contamination, nor can they attack bacterial species that are different from those specifically recognised.
  • the probiotics reduce the contaminant load slowly but constantly, thanks to the competitive mechanisms, inhibiting the recontamination and with an action that is independent of the microbial species present.
  • the contemporaneous presence of probiotics and bacteriophages guarantees the rapidity of the specific antimicrobial action and contemporaneous inhibition of recontamination, ensuring destruction of the pathogen that is rapid and stable over time.
  • the realising of a product for cosmetic use containing at the same time Bacillus probiotics and anti-pathogen bacteriophages has the obvious advantage, with respect to traditional products, of ensuring and extremely rapid and immediate destruction of the contaminant bacterial load.
  • the presence of the bacteriophages thus represents an empowering of the anti-bacterial action of the product bases on only probiotic Bacillus as it facilitates and increases the action of the probiotics, which are also active on fungi.
  • the predetermined families of bacteriophage elements can be present in the product that is the object of the invention, both singly and in combination, so as to include the possibility of diversified treatments according to the specific need. From the above it is clear that the detergent product for cosmetic use of the invention is able to active in a particularly rapid and effective way against any potentially-dangerous microbial species, including those of the multi- resistant type (superbugs). The product is particularly effective for cosmetic treatment of the skin and skin adnexa, hair, nails, and the oral cavity, mucosa or teeth, i.e. for cleansing thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)

Abstract

The detergent product for cosmetic use, comprises: a base compound having a detergent action; spores of probiotic bacteria mixed with the base compound; bacteriophage elements mixed with the base compound and having bactericide activity on predetermined undesired bacterial species present, the bacteriophage elements, in cooperation with the spores of probiotic bacteria, being able to carry out a combined and synergic action against damaging micro-organisms. Use of the detergent product is also described, for cleansing of the skin, skin adnexa (hair, nails, body hair, beard), of the oral cavity, mucosa or the teeth.

Description

DETERGENT PRODUCT FOR COSMETIC USE
DESCRIPTION OF THE INVENTION FIELD OF THE INVENTION
The present invention relates to the technical sector relating to cosmetic treatments for topical use, in the field of detergents.
There is at present a progressively growing demand for products for cleansing and caring for the skin and its adnexa (hair, keratin fibres, body hair, nails, beard) of the oral cavity, the mucosa and the teeth, based on natural, non-allergenic and biological formulations. DESCRIPTION OF THE PRIOR ART
Many of the products at present on the market for the cleansing/sanitising of the skin are based on the presence of chemical and/or pharmacological additives, which have the aim of preventing the onset of infections/inflammation, or of facilitating the restoring of the skin functions following the development of infections/inflammation of the skin and the adnexa.
It is known that the skin and its adnexa (hair, keratin fibres, body hair, nails, beard), the oral cavity, mucosa and teeth, are colonised by numerous micro-organisms (especially bacteria and fungi), which in their entirety form the cutaneous commensal microbiota.
However, the presence of some types of micro-organisms on the skin, the oral cavity, the mucosa and teeth, can constitute a risk for development of infections or inflammations.
As the presence of benign non-pathogenic micro-organisms effectively opposes colonisation by potentially pathogenic micro-organisms, the Applicant notes that there already exist detergent products on the free market, under the name of BI-SAFE® (Probiotic Hygiene and Care Hand Soap, Chrisal), which contain probiotic bacteria of the Bacillus genus, with the aim of limiting the use of chemical disinfectants and facilitating a benign colonisation of the skin, so that the skin can combat pathogenic micro-organisms and render their population difficult.
These products exploit a "biocontrol" approach based on the fact that the probiotic micro-organisms (non-pathogens) can colonise the skin and the adnexa, competing with the proliferation of other species that are potentially risky for the health of individuals.
The bacteria of the Bacillus genus represent a vast group of spore-forming Gram-positive bacteria, ubiquitous in nature and also present in the human intestine.
The spores formed by the Bacillus bacteria can survive for very long times, because of their resistance to desiccation, heat and many chemical substances, and are therefore ideal for probiotic applications in the field of cosmetics. It is also noteworthy that from the point of view of safety, the Bacillus species present in the products used are considered low/null risk for pathogens (non-pathogenic).
The presence of the probiotics further prevents re-colonisation by contaminant micro-organisms, thus stably maintaining the hygiene where the probiotics are applied.
As this is a system based on the biological mechanism of competitive antagonism between probiotics and contaminant microbes, it can however be necessary to make prolonged use in order to reach the stable destruction of the potentially harmful microbial load. SUMMARY OF THE INVENTION
An aim of the present invention is to obviate the above drawbacks by providing a detergent product for cosmetic use able to act rapidly and effectively against any potentially-dangerous microbial species, including those of the multi-resistant type (superbugs). The above-indicated aims are obtained by a cosmetic product realised according to claim 1 , and a use of the cosmetic product according to claim 10.
In particular embodiments, the product for cosmetic use comprises the following compounds, in combination:
• the base compound can be in the solid, liquid or gaseous state;
• the base compound can comprise at least cationic surfactants, anionic surfactants or amphoteric compounds or mixtures thereof;
• the base compound can comprise: PEG-6-caprylic/capric glycerides; Sodium laureth sulfate; Sodium lauryl sulfate; Acrylates/steareth-20 methacrylate copolymer; phenoxyethanol; ethylhexylglycerin, potassium hydroxide;
• the probiotic bacteria spores are mixed with the base compound at a concentration comprised between 102-109 spores/ml; · the bacteriophage elements are mixed with the base compound at a concentration comprised between 103-109 PFU/ml;
• the probiotic bacteria are of the Bacillus genus (preferably though not exclusively of the species Bacillus subtilis, Bacillus megaterium and Bacillus pumilus); · the bacteriophage elements comprise bacteriophages of the family Caudovirales and/or of the family Microviridae and/or of the family Leviviridae and/or of the family Inoviridae and/or of the family Tectiviridae and/or of the family Corticoviridae;
The characteristics of the invention are specified in the following in which some preferred, but not exclusive, embodiments are described.
BREVE DESCRIPTION OF THE DRAWINGS
Figures 1-3 are graphs relating to colonisation over time, respectively to Staphylococcus aureus, Enterobacteriaceae spp. Gram negative) and Candida albicans, on surfaces treated with probiotic bacteria.
Figures 4-6 are graphs relating to colonisation over time, respectively to Staphylococcus aureus, Enterobacteriaceae spp. Gram negative) and Candida albicans, on surfaces treated with bacteriophages.
Figures 7-9 are graphs relating to colonisation over time, respectively to Staphylococcus aureus, Enterobacteriaceae spp. Gram negative) and Candida albicans, on surfaces treated with bacteriophages and with probiotic bacteria. Figure 10 is a graph relating to colonisation over time, with respect to Staphylococcus aureus on surfaces treated with probiotic bacteria and with bacteriophages, with respect to surfaces treated only with probiotic bacteria and only with bacteriophages.
The proposed detergent product for cosmetic use innovatively comprises: - a base compound having a detergent action;
- spores of probiotic bacteria mixed with the base compound;
- bacteriophage elements mixed with the base compound and having bactericide activity on predetermined undesired bacterial species present, the bacteriophage elements, in cooperation with the spores of probiotic bacteria, being able to carry out a combined and synergic action against damaging micro-organisms.
The field of the invention also includes the use of the detergent product for cosmetic use for cleansing of the skin, skin adnexa (hair, body hair, keratin fibres, nails, beard), of the oral cavity, mucosa (in particular of the oral cavity) and the teeth. It is particularly advantageous for the cleansing of the skin, skin adnexa, hair, nails, body hair, beard, for external intimate hygiene.
The base compound can comprise one or more of the following: PEG-6- caprylic/capric glycerides; Sodium laureth sulfate; Sodium lauryl sulfate; Acrylates/steareth-20 methacrylate copolymer; phenoxyethanol; ethylhexylglycerin, potassium hydroxide. To these can also be added cocamidopropyl betaine and dodecyl-betaine. The spores of probiotic bacteria can be present in the detergent product of the invention, at a concentration comprised between 102-109 spore/ml, preferably from 105-109 spore/ml, more preferably 106-108 spore/ml.
The bacteriophage elements specifically directed against bacteria potentially able to cause infection/inflammation of the skin or adnexa can be present in the detergent product of the invention, at a concentration comprised between 103-109 spore/ml, preferably from 105-109 spore/ml, more preferably 106-108 spore/ml.
By way of non-limiting example, the probiotic bacteria can be of the Bacillus genus, including the species Bacillus subtilis, Bacillus megaterium and Bacillus pumilus.
This does not exclude the possibility that further probiotic bacteria can be used, as a function of the undesired bacterial species to be compared and contrasted.
The bacteriophage element can advantageously be selected, alternatively or in combination, according to the bacterial species to be compared, from among the following families: Caudovirales, Microviridae, Leviviridae, Inoviridae, Tectiviridae, Corticoviridae.
As is known, the bacteriophage elements of the Caudovirales family also comprise the Myoviridae, Siphoviridae, Podoviridae families. The detergent product of the invention for cosmetic use, in the preferred embodiments as indicated in the foregoing, is particularly suitable for cleansing of the skin, skin adnexa (hair, body hair, keratin fibres, nails), the oral cavity, the mucosa (in particular of the oral cavity) and teeth.
It can be produced in the solid state (for example for soaps, powders etc.) or in the liquid state (for example creams, lotions, gels, foams etc.) or in the gaseous state (for example for sprays etc.) or an emulsion or a suspension or a paste (for example a toothpaste).
The detergent product for cosmetic use can be advantageously a toothpaste, a soap, a beauty soap, a deodorant soap, a depilating soap, a shaving soap or foam, a make-up removing product for the face and/or eyes (for example a detergent milk, micellar water, tonic), a foam bath, a shower bath, an intimate detergent for external use, a liquid shampoo, a powder shampoo, a hair conditioner balsam, a deodorant, an anti-perspirant product, or a bath salt. Preferably the detergent product for cosmetic use is a toothpaste, a soap, a beauty soap, a deodorant soap, a depilating soap, a shaving soap or foam, a make-up removing product for the face and/or eyes (for example a detergent milk, micellar water, tonic), a foam bath, a shower bath, an intimate detergent for external use, a liquid shampoo, or a powder shampoo. In particular, bath and/or shower products can be in liquid form, such as a liquid detergent product, a foam, oils, gels, or they can be in the form of salts and are preferably a liquid detergent, and oil or a gel.
In a preferred embodiment of the invention, the detergent product for cosmetic use of the invention is a product for shaving such as, for example, a shaving cream, foam or lotion, or a depilating soap, and more preferably it is a cream, a shaving foam or a depilating soap. Note that where there is a beard or profuse body hair there is a greater colonisation of numerous micro-organisms and a tendency to inflammation of the shaven and/or depilated skin and that the shaving creams or foams and the depilating soaps of known type comprise a base compound having a detergent activity and in fact once rinsed they cleanse the skin and the adnexa.
Therefore the use of the detergent product for cosmetic use according to the invention for shaving or depilation is preferred. In a further aspect of the invention, the detergent product for cosmetic use of the invention is a product for oral hygiene, in particular a toothpaste, in particular if in paste, gel or powder form. The use thereof for cleaning the teeth and/or the mucous membranes of the oral cavity is consequently advantageous. In a further embodiment of the detergent product of the invention, the detergent product for cosmetic use of the invention is a make-up removal detergent for the face and/or eyes. It is consequently advantageous to use the product for cleansing the face and/or the eyes of make-up.
The action of the bacteriophages is specific, as specific types of lithic bacteriophages kill specific types of bacteria, and therefore perform a potentially very effective and specific action in the direct battle against undesired bacteria.
It is further evidenced how the use of specific bacteriophages prevents the risk of damage to the probiotic Bacillus, which can therefore be kept intact and effective in their activity.
The use of bacteriophages in detergent products for cosmetic use is particularly indicated as they are rather stable in differing temperature conditions, pH and salinity of the environment, and can therefore be added to base compounds without suffering in terms of activity and without the base compound losing detergent activity.
As the Applicant is not at present empowered to carry out laboratory testing on animals or human beings, it has used alternative methods to carry out experimental testing on inert surfaces.
These laboratory test give evidence of the synergic effect deriving from the combined use of probiotic bacteria and bacteriophage elements with respect to the single use of probiotic bacteria or bacteriophage elements.
Test n° 1 (use only of probiotic bacteria)
The activity of PCHS detergents containing probiotics has been amply evaluated on inert surfaces, where they have shown themselves to be able to destroy the microbial load by about 90% more with respect to traditional detergents, with protracted use for about one month.
After a period of two months destruction, the contaminant load is stably low regarding both the bacteria and the fungi [Caselli et al., 2016]. Figures 1 -3 illustrate the antimicrobial action (bacteria and fungi) of detergent product based only on probiotics.
The trend of contamination by Staphylococcus aureus (taken as an example of Gram positive bacteria), Enterobacteriaceae spp. (as an example of Gram negative bacteria) and Candida albicans (as an example of fungi), was measured on the field, with application of Rodac plates of specific media for the indicated bacteria and fungi species.
Test n° 2 (use only of bacteriophages)
Figure 4-6 illustrate the anti-bacterial action of the bacteriophages on an inert surfaces contaminate by specific target bacteria. The trend of contamination by Staphylococcus aureus (taken as an example of Gram positive bacteria), Pseudomonas aeruginosa (as an example of Gram negative bacteria) and Candida albicans (as an example of fungi), was measured in vitro, on experimental models of inert surfaces having an area of 24 cm2. The surfaces were contaminated with a known quantity of micro-organism (102 CFU/24 cm2) and then treated by application of growing concentrations of specific bacteriophages (respectively 103, 104, 105 PFU), therefore in ratios of 10:1 , 100:1 and 1000:1 with the seeded target bacteria.
For the fungi a combination of the bacteriophages used against the Gram positive and Gram negative bacteria was used.
The residual contamination was evaluated after 1 , 3, 6 hours by application of Rodac plates of specific medium for the indicated bacterial and fungi species. The results are expressed as mean values ± S.D. of samples in duplicate in three independent experiments.
It can be noted that already after one hour, and at the lower concentration, the bacteriophages are able to remove more than 90% of the bacterial cells against which they are specifically directed.
The treatment with only bacteriophages has the limitation of being directed only against the bacteria specifically recognised by the bacteriophages, and therefore in a case of contamination by bacterial species different from those against which the bacteriophages are specifically directed, the surface treated is contaminated by the species not attacked by the bacteriophages, as the bacteriophages are by definition specific for a bacterial species, and therefore not able to attack other bacterial species, not are they able to attack species of fungi.
These limitations of the bacteriophages are overcome by the addition of the probiotics, which instead have a slower action, but generalised and independent of the bacterial or fungi species present.
Test n° 3 (combined use of probiotic bacteria / bacteriophages)
Figures 7-9 illustrate the effect of the combined and synergic antimicrobial action obtained with the contemporary presence of probiotic bacteria and bacteriophages on surfaces contaminated by the specific microbes illustrated.
The trend of contamination by Staphylococcus aureus (taken as an example of Gram positive bacteria), Pseudomonas aeruginosa (as an example of Gram negative bacteria) and Candida albicans (as an example of fungi), was measured in vitro, on experimental models of inert surfaces of non-porous and sterile material having an area of 24 cm2.
The surfaces were contaminated with a known quantity of micro-organism (103 CFU/24 cm2) and then treated by application of a solution containing probiotic bacteria growing concentrations of (103 CFU/ml) and specific bacteriophages (104 PFU/ml).
For the fungi a combination of the bacteriophages used against the Gram positive and Gram negative bacteria was used.
The residual contamination was evaluated after 1 , 2, 3 and 4 hours by application of Rodac plates of specific medium for the indicated bacterial and fungi species. The results are expressed as mean values ± S.D. of samples in duplicate in three independent experiments.
Comparison of the tests carried out
Figure 10 illustrates the direct comparison between the antimicrobial action of the no. 3 treatments on the contamination by Staphyococcus aureus, measured in vitro on experimental models of inert surfaces of 24 cm2.
The surfaces were contaminated with a known quantity of micro-organism (103 CFU/24 cm2) and then treated by application of a solution containing probiotic bacteria growing concentrations of (103 CFU/ml), only specific bacteriophages (104 PFU/ml), or the combination of probiotics and bacteriophages at the indicated concentrations.
The residual contamination was evaluated after 1 , 2, 3 and 7 hours by application of Rodac plates of specific medium for Staphyococcus aureus.
The results are expressed as mean values ± S.D. of samples in duplicate in three independent experiments.
From the experimental tests carried out, it can easily be noted how the contemporaneous presence of Bacillus probiotics and anti-pathogen bacteriophages significantly increases the effectiveness of the detergent product for cosmetic use, thanks to the synergic action carried out against the various damaging micro-organisms.
On the one hand the bacteriophages destroy the contaminant load extremely rapidly, but have a limited action over time and do not succeed in preventing re-contamination, nor can they attack bacterial species that are different from those specifically recognised.
On the other hand the probiotics reduce the contaminant load slowly but constantly, thanks to the competitive mechanisms, inhibiting the recontamination and with an action that is independent of the microbial species present.
The contemporaneous presence of probiotics and bacteriophages guarantees the rapidity of the specific antimicrobial action and contemporaneous inhibition of recontamination, ensuring destruction of the pathogen that is rapid and stable over time. The realising of a product for cosmetic use containing at the same time Bacillus probiotics and anti-pathogen bacteriophages has the obvious advantage, with respect to traditional products, of ensuring and extremely rapid and immediate destruction of the contaminant bacterial load.
This is thanks to the combined action performed by the bacteriophages which are able, in a few hours, to kill the target bacteria, and by the probiotic bacteria, which are able to persistently colonise the cutaneous surface, replacing the pathogens.
The presence of the bacteriophages thus represents an empowering of the anti-bacterial action of the product bases on only probiotic Bacillus as it facilitates and increases the action of the probiotics, which are also active on fungi.
This guarantees an immediate sanitising effect during the initial step of the cosmetic treatment, enabling the probiotic bacteria to maintain a stably low presence over time of potentially pathogenic bacteria. The addition of specific bacteriophage elements to the base compound mixed with spores of probiotic Bacillus advantageously enables using the product in a directed way, responding to specific needs and/or situations of particular interest, such as for example the destruction of one or more specific bacterial species that are particularly prevalent and/or damaging. The presence in the product of the invention of a greater number of families of bacteriophage families (Caudovirales, Microviridae, Leviviridae, Inoviridae, Tectiviridae and Corticoviridae) enables the product itself to have a bactericide activity on a broader group of treatable bacterial species.
The predetermined families of bacteriophage elements can be present in the product that is the object of the invention, both singly and in combination, so as to include the possibility of diversified treatments according to the specific need. From the above it is clear that the detergent product for cosmetic use of the invention is able to active in a particularly rapid and effective way against any potentially-dangerous microbial species, including those of the multi- resistant type (superbugs). The product is particularly effective for cosmetic treatment of the skin and skin adnexa, hair, nails, and the oral cavity, mucosa or teeth, i.e. for cleansing thereof.

Claims

1) A detergent product for cosmetic use, comprising: a base compound having a detergent action; spores of probiotic bacteria mixed with the base compound; characterised in that it further comprises bacteriophage elements mixed with the base compound and having bactericide activity on predetermined undesired bacterial species present, the bacteriophage elements, in cooperation with the spores of probiotic bacteria, being able to carry out a combined and synergic action against damaging microorganisms. 2) The product of claim 1 , characterised in that the base compound can be in the solid, liquid or gaseous state.
3) The product of claim 1 or 2, characterised in that the base compound comprises one or more of following compounds: PEG-6-caprylic/capric glycerides; Sodium laureth sulfate; sodium lauryl sulfate; Acrylates/steareth- 20 methacrylate copolymer; phenoxyethanol; ethylhexylglycerin, potassium hydroxide.
4) The product of one of claims from 1 to 3, characterised in that the probiotic bacteria spores are mixed with the base compound at a concentration comprised between 102-109 spores/ml. 5) The product of one of claims from 1 to 4, characterised in that the bacteriophage elements are mixed with the base compound at a concentration comprised between 103-109 PFU/ml.
6) The product of one of claims from 1 to 5, characterised in that the probiotic bacteria are of the Bacillus genus. 7) The product of claim 6, characterised in that the probiotic bacteria are of the species Bacillus subtilis, Bacillus megaterium and Bacillus pumilus.
8) The product of one of claims from 1 to 7, characterised in that the bacteriophage elements comprise bacteriophages of the family Caudovirales and/or of the family Microviridae and/or of the family Leviviridae and/or of the family Inoviridae and/or of the family Tectiviridae and/or of the family Corticoviridae.
9) The product according to any one of claims from 1 to 8, wherein the product is a product selected from a group constituted by a toothpaste, a soap, a beauty soap, a deodorant soap, a depilating soap, a shaving soap or foam, a make-up removing product for the face and/or eyes, a foam bath, a shower bath, an intimate detergent for external use, a liquid shampoo, a powder shampoo, a hair conditioner balsam, a deodorant, an anti-perspirant product, and a bath salt. 10) Use of a detergent product for cosmetic use, as in any one of claims from 1 to 9, for cleansing of the skin, skin adnexa, hair, nails, body hair, beard, oral cavity, mucosa or teeth.
11 ) Use according to the preceding claim, for shaving and/or depilation.
12) Use according to the preceding claim, for cleansing make-up from the face and/or the eyes.
13) Use according to the preceding claim, for cleansing of the skin, skin adnexa, hair, nails, body hair, beard, for external intimate hygiene.
EP17791732.5A 2016-09-22 2017-09-21 Detergent product for cosmetic use Active EP3515563B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
RS20211118A RS62316B1 (en) 2016-09-22 2017-09-21 Detergent product for cosmetic use
PL17791732T PL3515563T3 (en) 2016-09-22 2017-09-21 Detergent product for cosmetic use
SI201730893T SI3515563T1 (en) 2016-09-22 2017-09-21 Detergent product for cosmetic use
HRP20211440TT HRP20211440T1 (en) 2016-09-22 2017-09-21 Detergent product for cosmetic use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102016000095070A IT201600095070A1 (en) 2016-09-22 2016-09-22 CLEANSING PRODUCT FOR COSMETIC USE
PCT/IB2017/055740 WO2018055553A1 (en) 2016-09-22 2017-09-21 Detergent product for cosmetic use

Publications (2)

Publication Number Publication Date
EP3515563A1 true EP3515563A1 (en) 2019-07-31
EP3515563B1 EP3515563B1 (en) 2021-08-18

Family

ID=57909931

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17791732.5A Active EP3515563B1 (en) 2016-09-22 2017-09-21 Detergent product for cosmetic use

Country Status (24)

Country Link
US (1) US11123579B2 (en)
EP (1) EP3515563B1 (en)
JP (1) JP7121400B2 (en)
KR (1) KR102485915B1 (en)
CN (1) CN109906106B (en)
AU (1) AU2017332870B2 (en)
BR (1) BR112019005622B1 (en)
CA (1) CA3037650A1 (en)
CY (1) CY1125518T1 (en)
DK (1) DK3515563T3 (en)
ES (1) ES2890274T3 (en)
HR (1) HRP20211440T1 (en)
HU (1) HUE055475T2 (en)
IL (1) IL265493B (en)
IT (1) IT201600095070A1 (en)
LT (1) LT3515563T (en)
MX (1) MX2019003342A (en)
PL (1) PL3515563T3 (en)
PT (1) PT3515563T (en)
RS (1) RS62316B1 (en)
RU (1) RU2748654C2 (en)
SI (1) SI3515563T1 (en)
WO (1) WO2018055553A1 (en)
ZA (1) ZA201902364B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112516068A (en) * 2020-12-15 2021-03-19 福建洛东生物技术有限公司 Application of bacillus subtilis in antibacterial, deodorizing and cleaning products

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918983D0 (en) * 1989-08-21 1989-10-04 Unilever Plc Composition for hygiene purposes
US6387874B1 (en) * 2001-06-27 2002-05-14 Spartan Chemical Company, Inc. Cleaning composition containing an organic acid and a spore forming microbial composition
US20070054357A1 (en) * 2005-09-06 2007-03-08 Pasternack Gary R Identification of useful bacteriophage
KR100924661B1 (en) * 2007-08-16 2009-11-03 주식회사 인트론바이오테크놀로지 Podoviridae Bacteriophage Having Killing Activity Specific to Staphylococcus aureus
EP2585036A2 (en) 2010-06-24 2013-05-01 Novozymes Biologicals Inc. Methods and compositions for reducing body odor
GB2484134B (en) * 2010-10-01 2013-01-30 Cleveland Biotech Ltd Cleaning compositions
US10071159B2 (en) * 2011-01-31 2018-09-11 Colgate-Palmolive Company Oral care compositions
KR101432872B1 (en) 2011-09-20 2014-08-27 씨제이제일제당 (주) Novel bacteriophage and antibacterial composition comprising the same
KR101466620B1 (en) * 2012-06-22 2014-11-28 주식회사 씨티씨바이오 Novel bacteriophage and its use for preventing proliferation of Aeromonas hydrophila
KR101381797B1 (en) 2013-02-27 2014-04-07 씨제이제일제당 (주) Novel bacteriophage and antibacterial composition comprising the same
ITUB20150028A1 (en) * 2015-04-22 2016-10-22 Copma S C A S R L PRODUCT FOR CLEANING, SANITIZATION AND SANITIZATION

Also Published As

Publication number Publication date
HUE055475T2 (en) 2021-11-29
RU2748654C2 (en) 2021-05-28
IT201600095070A1 (en) 2018-03-22
IL265493B (en) 2022-09-01
LT3515563T (en) 2021-09-10
ZA201902364B (en) 2019-12-18
CY1125518T1 (en) 2024-02-16
PT3515563T (en) 2021-09-02
JP7121400B2 (en) 2022-08-18
CN109906106A (en) 2019-06-18
MX2019003342A (en) 2019-09-26
US11123579B2 (en) 2021-09-21
PL3515563T3 (en) 2021-12-13
AU2017332870A1 (en) 2019-05-02
RU2019111159A (en) 2020-10-22
HRP20211440T1 (en) 2021-12-24
AU2017332870B2 (en) 2023-07-06
EP3515563B1 (en) 2021-08-18
BR112019005622B1 (en) 2022-12-20
IL265493A (en) 2019-05-30
DK3515563T3 (en) 2021-09-13
US20200038316A1 (en) 2020-02-06
CA3037650A1 (en) 2018-03-29
RU2019111159A3 (en) 2020-11-17
ES2890274T3 (en) 2022-01-18
JP2019529448A (en) 2019-10-17
CN109906106B (en) 2022-02-18
BR112019005622A2 (en) 2019-06-18
WO2018055553A1 (en) 2018-03-29
KR102485915B1 (en) 2023-01-05
KR20190056383A (en) 2019-05-24
RS62316B1 (en) 2021-09-30
SI3515563T1 (en) 2021-11-30

Similar Documents

Publication Publication Date Title
Kolhapure Evaluation of the antimicrobial efficacy and safety of PureHands herbal hand sanitizer in hand hygiene and on inanimate objects
EA024551B1 (en) Personal cleaning composition
AU2017332870B2 (en) Detergent product for cosmetic use
EP2787825A1 (en) Antimicrobial composition
WO2019032901A1 (en) Uv-detectable antibacterial compositions
EA036976B1 (en) Topical composition
WO2018134745A1 (en) A eutrophicating product for cosmetic use and a relative use
CA2889432C (en) Antibacterial hair removal composition
US20220054384A1 (en) Microbiostatic soap that reduces the transmission of microbes
Al-Rawi Novel natural disinfectants for contaminated cosmetic application tools
EP2787820B2 (en) Antimicrobial composition
JPWO2018055553A5 (en)
WO2019078796A2 (en) Antibacterial clay
EP2787821B2 (en) Antimicrobial composition
KR980008216A (en) A cleanser composition containing a lichen extract
EP2793577B1 (en) Antimicrobial method and composition
EA043004B1 (en) ANTIMICROBIAL COMPOSITION
RU2224502C2 (en) Dermal antiseptic composition and a method for preparation thereof
KR20060099711A (en) Composition for a wash & the wash containing the composition thereof
JP2000143440A (en) Bactericidal agent comprising string-shaped giant micelle
JPS6078909A (en) Cleaning and sterilizing agent to be compounded in cosmetic and perfumery

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20211440T

Country of ref document: HR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190416

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200422

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RIC1 Information provided on ipc code assigned before grant

Ipc: A61Q 19/10 20060101ALI20210201BHEP

Ipc: C11D 3/38 20060101ALI20210201BHEP

Ipc: A61K 8/99 20170101ALI20210201BHEP

Ipc: A01N 63/10 20200101ALI20210201BHEP

Ipc: A61Q 17/00 20060101AFI20210201BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210319

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3515563

Country of ref document: PT

Date of ref document: 20210902

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20210827

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017044368

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210909

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1421088

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210915

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

Ref country code: NO

Ref legal event code: T2

Effective date: 20210818

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 38110

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20210402293

Country of ref document: GR

Effective date: 20211013

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E021356

Country of ref document: EE

Effective date: 20210910

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E055475

Country of ref document: HU

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20211440T

Country of ref document: HR

Payment date: 20210917

Year of fee payment: 5

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20211440

Country of ref document: HR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2890274

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20220118

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017044368

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220519

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20211440

Country of ref document: HR

Payment date: 20220909

Year of fee payment: 6

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1421088

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210818

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20211440

Country of ref document: HR

Payment date: 20230912

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230918

Year of fee payment: 7

Ref country code: RO

Payment date: 20230913

Year of fee payment: 7

Ref country code: NO

Payment date: 20230922

Year of fee payment: 7

Ref country code: EE

Payment date: 20230921

Year of fee payment: 7

Ref country code: CZ

Payment date: 20230912

Year of fee payment: 7

Ref country code: AT

Payment date: 20230921

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230912

Year of fee payment: 7

Ref country code: SI

Payment date: 20230907

Year of fee payment: 7

Ref country code: SE

Payment date: 20230920

Year of fee payment: 7

Ref country code: RS

Payment date: 20230907

Year of fee payment: 7

Ref country code: PL

Payment date: 20230915

Year of fee payment: 7

Ref country code: HU

Payment date: 20230922

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20230912

Year of fee payment: 7

Ref country code: LV

Payment date: 20230918

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231010

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230927

Year of fee payment: 7

Ref country code: DE

Payment date: 20231011

Year of fee payment: 7

Ref country code: CY

Payment date: 20230919

Year of fee payment: 7

Ref country code: CH

Payment date: 20231001

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20230915

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20230913

Year of fee payment: 7

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20211440

Country of ref document: HR

Payment date: 20240912

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20240910

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20240924

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20240918

Year of fee payment: 8

Ref country code: LT

Payment date: 20240827

Year of fee payment: 8

Ref country code: IE

Payment date: 20240826

Year of fee payment: 8

Ref country code: MC

Payment date: 20240920

Year of fee payment: 8

Ref country code: HR

Payment date: 20240912

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240923

Year of fee payment: 8

Ref country code: DK

Payment date: 20240923

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240920

Year of fee payment: 8

Ref country code: PT

Payment date: 20240912

Year of fee payment: 8

Ref country code: SM

Payment date: 20240906

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240918

Year of fee payment: 8

Ref country code: LU

Payment date: 20240918

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240925

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240918

Year of fee payment: 8